by Mark Curtis | Oct 14, 2014
. Welcome to your Update from the Clinic for the month of September. There’s a mixture of news from the cancer stem cell companies and immunotherapy companies this past month. Amongst other things, the FDA removed the previously imposed partial hold on one of...
by Stacey Johnson | Sep 26, 2014
. An interest and appetite for science appears to be alive and well in two jurisdictions where high school students competed for the chance to spend part, or all, of their summer learning about stem cells and biomedical research. The winners of a science animation...
by David Brindley | Sep 16, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. Consider this question: if I gave you the option to take a drug offering a 100 percent chance...
by Mark Curtis | Sep 11, 2014
. Welcome to your deal review for the month of August. As would be expected at the end of the summer news flow was modest, but Northwest Biotherapeutics kept things alive with a $17.5 million financing via convertible debt, while Gamida Cell announced a game-changing...
by David Brindley | Sep 9, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. ‘Bay Area biotechnology’ is a description that conjures images of the proud Hoover Tower...
by Mark Curtis | Aug 18, 2014
. Welcome to your Update from the Clinic for the month of July. The cancer stem cell companies were back in the news last month. OncoMed initiated its ALPINE clinical trial of Tarextumab for pancreatic cancer, while Stemline Therapeutics announced an investigational...
Comments